loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Cipla highlighted its investment of ~₹4,000 crore over the past two years to expand its respiratory API

ICICIdirect Research 17 Jun 2026 DISCLAIMER

News: In recent annual report Cipla highlighted its investment of ~₹4,000 crore over the past two years to expand its respiratory API, oncology API, inhalation and complex dosage manufacturing capabilities across India, China and the US. The company has commissioned a greenfield respiratory API facility at Kurkumbh and is scaling capacities at Bommasandra, Goa, Sikkim and Patalganga. Cipla is also expanding its global inhalation network with additional respule lines in India and China, while its US MDI and DPI facilities support commercialisation of key respiratory products. Further, the company continues to strengthen its complex product pipeline, filing 10 USFDA applications in FY26 across respiratory inhalation products, peptide injectables and complex generics

View: Cipla's aggressive capacity expansion reinforces its strategic pivot towards complex and specialty therapies, which offer higher entry barriers and superior margin potential, while strengthening its global manufacturing and supply chain capabilities. We believe the company is well positioned for sustained growth, backed by a differentiated US pipeline of complex products, a long-term India strategy spanning branded Rx, trade generics and consumer health, and continued momentum in the South African business.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere